Renal impairment in β thalassemia major patients receiving repeated blood transfusion

Riadi Wirawan*, Simon Kusnandar*, Abas Suherli*, Djajadiman Gatot†

Abstract

β-thalassemia major is a disease caused by β polypeptide chain synthesis disorder which is inherited in an autosomal recessive manner from both parents and which is marked by little or no β- globin chain synthesis. Treatment for β-thalassemia major patients is by giving repeated blood transfusions, which causes iron accumulation, leading to hemochromatosis. Iron accumulation can occur in various body organs, including the kidneys. The aim of this study was to investigate the existence of renal impairment in β-thalassemia major patients. The subjects of this study were β-thalassemia major patients aged 15 - 28 years old who had received 6 units of packed red cells or more within 6 months. In this study, urine and serum samples of the subjects were taken and examined. Assay of serum iron was performed with Hitachi 737. Results were that 94.7% patients showed an increase in transferrin saturation and 40% of them had hemochromatosis; 73.4% had microalbuminuria; 1.3% had albuminuria and 21.3% had increased urinary β2-microglobulin (β2-m). A total of 78.6% of patients showed renal impairment. Conclusion of this study suggested that glomerular dysfunction happens in an earlier stage of the disease process. The high incidence of microalbuminuria is also attributed to defective ability of the proximal tubular cells to reabsorb protein besides dysfunction of the glomeruli. (Med J Indonesia 2003; 12: 215-223)

Keywords: β-thalassemia major, repeated blood transfusion, renal impairment

There are several means to assess renal function. The most frequently used test to estimate glomerular filtration rate (GFR) is the creatinine clearance test (CCT). Glomerular permeability can be evaluated through urinary albumin assessment, while renal tubular function is usually assessed by urinary β2-microglobulin (β2-m) measurement. Non-protein nitrogen (NPN) levels in blood, such as urea, creatinine and uric acid usually reflects excretory functions of the kidneys. The ability of the kidneys to retain or excrete water can also be measured.1,2,3

Ineffective hematopoiesis, hemolysis, increased iron absorption and repeated blood transfusion in β-thalassemia major patients will increase deposition of iron. Iron accumulation can occur in nearly all kinds of cells, but especially the reticuloendothelial cells in organs such as the spleen, liver, and bone marrow; it also occurs in the parenchymal cells in the heart, liver, kidneys, pancreas, and endocrine glands such as the Langerhans islets, the pituitary gland, testicles and ovaries.4,5,6,7 Inappropriate management in preventing iron accumulation will result in organ damage due to free radicals and lipid cell membrane peroxidation which is called hemochromatosis.5,8
Lack of data and research in the field of renal function in β thalassemia major patients receiving repeated blood transfusion and its relation to transferrin saturation led us to study the renal function through assessment of urinary β2-microglobulin and albumin levels, and correlate them with transferrin saturation.

**METHODS**

We evaluated 75 β thalassemia major patients attending the Thalassemia Center, Department of Child Health, Medical School, University of Indonesia, Dr. Cipto Mangunkusumo General Hospital between July 2001 and August 2001. Subjects were 15 years of age or older, willing to participate in this study, and had received 6 units of packed red cells or more within 6 months. Blood and urine samples were collected on the morning prior to the transfusion. All subjects had been well informed and had given their consent to participate in the study. The Committee for Research Ethics, Medical School, University of Indonesia had approved the study protocol.

Subjects with hypertension who were on medication that decreases creatinine excretion such as salicylates, cimetidine, trimethoprim, spironolactone and amiloride, were excluded from this study.²,³

Five ml of blood was drawn from the antecubital vein by sterile syringe without anticoagulant, and serum was obtained in a vacutainer after centrifugation at 4000 rpm for 10 minutes. Ten ml of midstream urine samples were collected in an appropriate urine container on the same morning. All procedures were done preceding the transfusion.

Reagent kits from Elitech were used for the analysis of serum iron (SI), total iron binding capacity (TIBC), ALT, AST, creatinine and microalbuminuria was conducted with a calibrator from Roche (cat no. 152298). Calibrator β2-m from Abbott (cat no. 2201-01) was used to calibrate the IMx for β2-microglobulin determinations.

Within run and between day precision tests was run on the Hitachi 737 using Precinorm U (PN) cat. no. 153213 and Precipath U (PP) cat. no. 152117, and for β2-microglobulin on the IMx with a three level control (cat. no. 2201-10).

A master table describing individual data: name, age, gender, and laboratory results (SI, TIBC, creatinine and microalbuminuria, β2-m, albumin/creatinine ratio, and β2-m/creatinine ratio) was made and a descriptive analysis done. Kolmogorov-Smirnov test for data distribution was carried out to determine the statistical correlation between β2-m, microalbuminuria and transferrin saturation. If the data distribution were normal, Pearson correlation test would be applied otherwise, the Spearman test would be used.¹⁰ All statistical tests were carried out using Statistical Product and Service Solution (SPSS) version 10.0 for Windows.

**RESULTS**

Within-run and between-day precision of all tests run on the Hitachi 737 with Precinorm U (PN) from Roche yielded the following results: AST (2.12% and 2.09%), ALT (2.93% and 3.63%), creatinine (3.29% and 3.40%), SI (4.22% and 4.57%), and TIBC (4.71% and 4.28%). The results of within-run and between-day precision of microalbumin run on the Hitachi 737 with microalbumin control were 2.10% and 1.92% (Table 1).

Accuracy tests run on the Hitachi 737 with PN from Roche yielded the following results: AST (~0.79%), ALT (+2.25%), creatinine (-0.66%), SI (+1.33%) and TIBC (+2.10%). The results of accuracy test for microalbumin on the Hitachi 737 using 100 mg/dL albumin solution was +2.00%. (Table 1)

Within-run and between-day precision of all tests run on the Hitachi 737 with Precipath U (PP) from Roche yielded the following results: AST (1.50% and 1.85%), ALT (1.75% and 2.31%), creatinine (3.11% and 3.30%), SI (3.28% and 3.74%), and TIBC (4.52% and 4.33%). (Table 1)
The results of accuracy tests run on the Hitachi 737 with PP from Roche were: AST (+3.04%), ALT (+2.71%), creatinine (+4.30%), SI (+4.78%) and TIBC (+1.16%). (Table 1)

The results of within run precision for B2-M on the IMx for Low (L), Medium (M) and High (H) controls were: 7.08%, 4.53% and 5.38% respectively. The accuracy of the test for L, M, and H controls was: +6.65%, +4.38% and +7.33% respectively (Table 2).

At least 73 β thalassemia major patients who met the criteria for this study were needed in order to show the proportion of elevated transferrin saturation, the minimal number of patients required to determine the correlation between elevated transferrin saturation and increased β2-m secretion and microalbuminuria was 29. The number of patients participating in this study was 75.

The profile of the participants were as follows; age between 15 and 28 years, body mass index between 11.0 and 23.4, transferrin saturation between 40.6 and 96.6%, AST and ALT activity between 24 and 276 U/l, and 16 and 292 U/l respectively. Urinary albumin excretion was between 4 and 360 mg/dl, while albumin/creatinine ratio was between 0.1 – 4.7 mg/mg. Urinary β2-m excretion was between 260 – 109,650 ng/dL, while β2-m /creatinine ratio was between 5.9 – 830 ng/mg. (Table 3)

### Table 1. Accuracy, within-run and between day precision using PN and PP Roche for SI, TIBC, AST, ALT, creatinine, and microalbumin control for microalbuminuria on the Hitachi 737

<table>
<thead>
<tr>
<th>Parameter</th>
<th>CV (%)</th>
<th>Within-run CV (%)</th>
<th>Between-day CV (%)</th>
<th>Within-run d (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NCCLS</td>
<td>PN</td>
<td>PP</td>
<td>PN</td>
</tr>
<tr>
<td>AST</td>
<td>3.57</td>
<td>2.12</td>
<td>1.50</td>
<td>2.09</td>
</tr>
<tr>
<td>ALT</td>
<td>3.97</td>
<td>2.93</td>
<td>1.75</td>
<td>3.63</td>
</tr>
<tr>
<td>Creatinine</td>
<td>8.9</td>
<td>4.22</td>
<td>3.11</td>
<td>3.40</td>
</tr>
<tr>
<td>SI</td>
<td>15</td>
<td>4.71</td>
<td>3.28</td>
<td>4.57</td>
</tr>
<tr>
<td>TIBC</td>
<td>15</td>
<td>4.41</td>
<td>4.52</td>
<td>4.28</td>
</tr>
<tr>
<td>Microalbuminuria</td>
<td>7.5</td>
<td>2.10</td>
<td></td>
<td>1.94</td>
</tr>
</tbody>
</table>

### Table 2. Precision and accuracy of β2-m tests on the IMx using β2-m control Abbott

<table>
<thead>
<tr>
<th>β2-m</th>
<th>Manufacturer CV (%)</th>
<th>CV (%)</th>
<th>d (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>7.4</td>
<td>7.08</td>
<td>6.65</td>
</tr>
<tr>
<td>Medium</td>
<td>7.6</td>
<td>4.53</td>
<td>4.38</td>
</tr>
<tr>
<td>High</td>
<td>5.4</td>
<td>5.38</td>
<td>7.33</td>
</tr>
</tbody>
</table>

### Table 3. Participants profile (n = 75 subjects)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Unit</th>
<th>n</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Reference value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Years</td>
<td>75</td>
<td>15</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Transferrin Saturation (TS)</td>
<td>%</td>
<td>75</td>
<td>40.6</td>
<td>96.6</td>
<td>&lt; 55</td>
</tr>
<tr>
<td>AST</td>
<td>U/L</td>
<td>75</td>
<td>24</td>
<td>176</td>
<td>&lt; 37</td>
</tr>
<tr>
<td>ALT</td>
<td>U/L</td>
<td>75</td>
<td>16</td>
<td>292</td>
<td>&lt; 41</td>
</tr>
<tr>
<td>Microalbuminuria</td>
<td>mg/dL</td>
<td>75</td>
<td>4</td>
<td>360</td>
<td>30 – 140</td>
</tr>
<tr>
<td>Urine Albumin/Creatinine ratio</td>
<td>mg/mg</td>
<td>75</td>
<td>0.1</td>
<td>4.7</td>
<td>&lt; 0.3</td>
</tr>
<tr>
<td>Urine β2-microglobulin</td>
<td>ng/dL</td>
<td>75</td>
<td>260</td>
<td>109,560</td>
<td>15,400</td>
</tr>
<tr>
<td>Urine β2-m /Creatinine ratio</td>
<td>ng/mg</td>
<td>75</td>
<td>5.9</td>
<td>830.0</td>
<td>&lt; 166</td>
</tr>
</tbody>
</table>
Seventy-one out of 75 subjects (94.7%) had a transferrin saturation of more than 55%, while 30 subjects (40%) had hemochromatosis (transferrin saturation of more than 55% associated by elevated transaminase activity of more than twice the reference value), refer to Figure 1.

Glomerular impairment was found in 56 subjects (74.7%), in which 55 (73.4%) subjects showed microalbuminuria, and albuminuria in one subject (1.3%), refer to Figure 2.

Tubular impairment (increased β2-m excretion) was found in 16 subjects (21.3%), refer to Figure 3.
Forty-three (57.3%) subjects had microalbuminuria, 12 (16.0%) subjects had microalbuminuria with increased β2-m excretion, 3 (4.0%) subjects had increased β2-m excretion and only 1 (1.3%) subject showed albuminuria with increased β2-m excretion. A total of 59 (78.6%) subjects showed renal impairment. (Fig 4.)

The scatter diagram in figure 5 and 6 shows glomerular impairment occurring at the age of 15 years, while tubular involvement is seen at 16 years of age.

The Kolmogorov-Smirnov (K-S) test showed a normal distribution (\( p > 0.05 \)). The Pearson’s Correlation test to determine the correlation between transferrin saturation and microalbuminuria and β2-m excretion were as follows: there was no correlation between transferrin saturation and microalbuminuria, β2-m excretion, urine albumin/creatinine ratio, urine β2-m/creatinine ratio. (Table 4)

We divided the subjects into two groups. The first group consisted of patients with hemochromatosis, the second group consisted of patients without hemochromatosis. We did a correlation test with the Kendall-tau b, and found no correlation between hemochromatosis and microalbuminuria, and albumin/creatinine ratio were found. (Table 4.) There was a very weak positive correlation (\( r = 0.327 \) dan \( p = 0.004 \)) between hemochromatosis and β2-m excretion, and also with β2-m/creatinine ratio (\( r = 0.298 \) dan \( p = 0.010 \)).
Figure 5. Scatter diagram showing glomerular impairment in β-thalassemia major patients

Figure 6. Scatter diagram showing tubular impairment in β-thalassemia major patients
DISCUSSION

Precision and accuracy for all test run on the Hitachi 737 met the requirements of the National Committee for Clinical Laboratory Standards (NCCLS) in International External Quality Assessment Scheme (IEQAS).\(^2\) Precision and accuracy for β2-m determination on the IMx also met the required recommendation of the manufacturer.\(^3\)

The reason for choosing an age group of more than 15 years old is the high probability that this group has had hemochromatosis. Without regular iron chelating regimen, β thalassemia major patients will develop organ damage due to iron deposit, which is called hemochromatosis.\(^5\) The normal reference range for transferrin saturation is 20 – 45%, in hemochromatosis the transferrin saturation is ≥ 55 % accompanied by increased ALT and AST activity of more than twice the reference value.\(^7,14\) Seventy one subjects (94.7%) out of 75 that participate in this study had a transferrin saturation of more than 55 %, 30 (40.0%) had hemochromatosis (Fig 1). This confirmed earlier studies that β thalassemia major patients receiving regular blood transfusion will experience iron accumulation, each unit of transfused blood contains 200 to 250 mg iron.\(^4\) After one year of receiving regular (once in 2 – 4 weeks) blood transfusion, iron accumulation will be found in the hepatic parenchym.\(^6\)

The amount of iron may exceed the serum transferrin capacity to bind iron, non transferrin bound iron forms free radicals and cause tissue damage through oxidative process in the cell membrane lipid, amino acid, protein, and nucleic acid.\(^5,8,7\) Organs usually influenced by iron accumulation are the liver, pancreas, heart, joints, and endocrine glands.\(^6\)

Besides damage to the cell membrane, oxidative process can also damage the mitochondria, lysosome and smooth endoplasmic reticulum (SER),\(^5\) causing elevated serum transaminase activity, which is considered as an indicator of hemochromatosis.

The normal glomerular capillary discriminates on the basis of size and acts as an electrostatic barrier to prevent albumin, globulin and other large molecule plasma proteins to pass. Proteins with a molecular weight less than 20,000 daltons could pass in minute amounts through the glomerular capillary, to be reabsorbed by the proximal tubular cells. Small molecules such as α2-microglobulin, β2-m, apoprotein, certain enzymes, and peptides, are normally excreted in small amounts into the urine. The average normal human excretes 30 to 130 mg protein/day.\(^1,2,3\)

Pyrogallol red–molybdate is a dye that gives a color reaction with albumin with a sensitivity of 97%, but also reacts with γ-globulin with a sensitivity of 70 %, Bence Jones type λ, with a sensitivity of 52%, and 68% for type κ, and 98% for hemoglobin.\(^6\)

Microalbuminuria is a condition in which urinary albumin excretion exceeds the normal limits but is less than clinical albuminuria (20 – 200 μg/min or 30 – 300 mg/24 h), which is 30 – 140 μg albumin/mL urine.\(^7\) To avoid 24 hour urine collections, the albumin/creatinine ratio is recommended. In an earlier study, Suryaningsih\(^16\) found that to predict albuminuria the albumin/creatinine ratio is better than urinary albumin determination, and correlated with 24 hour urinary albumin excretion. Microalbuminuria is represented by an albumin/creatinine ratio of 0.3 to 3 mg/dL, while albuminuria is depicted when the albumin/creatinine ratio is more than 3 mg/dL.\(^19\)

In our study the range of urinary albumin excretion was 4 – 360 mg/dL with an albumin/creatinine ratio of 0.1 – 4.7 mg/mg. Microalbuminuria was found in 55 (73.4%) subjects and albuminuria in one (1.3%) subject, 19 (25.3%) subjects had normal urinary albumin excretion (Fig 7).

Landing et al, as cited by Zhou et al,\(^10\) found hemosiderin deposit in the parietal epithelial cells and visceral glomerulus in patients with hemosiderosis. They also found large amounts of hemosiderin deposit in the proximal and distal renal tubuli.

There are two factors leading to albuminuria and microalbuminuria in β thalassemia major patients. First, iron deposit in the kidneys damages the glomerulus, causing an increased filtration of large molecular weight (> 20,000 daltons) plasma proteins which exceeds the tubular capacity to reabsorb. Second, indirectly through the diabetic kidney as a complication of iron accumulation in the pancreas.

β2-m is a protein with a molecular weight of 11,800 dalton, first extracted from a patient with tubular proteinuria by Berggard et al\(^15,21\) in 1968. This protein (β2-m) is found on the human cell surface expressing the major histocompatibility complex (MHC) class I, as a light chain attached to the heavy
chain of the MHC class I antigen. After the MHC class I antigen is released from the cell surface, it undergoes a proteolytic process and β2-m enters the circulation as a monomer, and can be found in the serum, and other body fluids.\textsuperscript{13,21} β2-m filtered through the glomerular membrane is nearly completely reabsorbed by the proximal tubular cells and degraded. Urinary β2-m excretion is a sensitive parameter to evaluate the proximal tubular function, and can be used to differentiate tubular dysfunction from glomerular dysfunction.\textsuperscript{13,21,22}

It has been reported that large amounts of hemosiderin deposit are found in the proximal and distal tubuli, causing atrophy of the proximal tubule in β thalassemia major patients.\textsuperscript{20}

Our study revealed a urinary β2-m excretion of between 260 – 109.560 ng/dL and a β2-m/creatinine ratio of between 5.9 – 830.0 ng/mg. Tubular dysfunction was found in 16 (21.3%) patients, with a β2-m/creatinine ratio > 166 ng/mg.

Reichert et al\textsuperscript{18} studied 30 patients with membranous nephropathy, and found 11 out of 14 patients with β2-m excretion of > 500 ng/min suffered from renal dysfunction, but only 2 out of 16 patients with β2-m excretion of < 500 ng/min suffered from renal dysfunction. Urinary β2-m excretion of > 500 ng/min has a 79% positive predictive value, and an 88% negative predictive value with 85% sensitivity and 82% specificity.

Ong-aijoooth et al\textsuperscript{23} who, studied 97 β thalassemia - HbE patients and 27 normal controls found a significant increase in urinary protein excretion, β2-m excretion, and N-acetyl beta-D-glucosaminidase (NAG). It is assumed that iron pile up caused tissue oxidative stress, which is expressed by increased malonyldialdehyde (MDA) in serum and urine.

Our study revealed 16 (21.3%) patients with tubular dysfunction; urinary β2-m determination could be used as a tool to assess renal tubular function.

It has been mentioned in earlier studies that β thalassemia major patients receiving repeated blood transfusion suffers from large amounts of haemosiderin deposits in the proximal and distal tubuli, the parietal epithelial cells, and visceral glomerulus.\textsuperscript{20}

In our study, most patients (55 or 73.4%) had microalbuminuria and one with albuminuria, while increased β2-m excretion was found in only 16 (21%) patients. This suggests that glomerular dysfunction occurs in an earlier stage of the disease process. There is, of course, a probability that tubular dysfunction already existed before β2-m excretion is increased which caused microalbuminuria through reduced ability of the tubular cells to reabsorb albumin from the filtrate. Our study also revealed that renal dysfunction could be detected in patients as young as 15 years old. (Figure 10 and 11)

Statistical analysis was used to look for correlation between increased transferrin saturation and microalbuminuria and increased urinary β2-m excretion, but no correlation was found between those parameters. Meanwhile a very weak positive correlation between hemochromatosis and increased urinary β2-m excretion and β2-m/creatinine ratio was found. This means that β thalassemia major patients with hemochromatosis are prone to renal dysfunction and this finding is in accordance with the autopsy findings of Grossman et al\textsuperscript{24} and Landing et al, as cited by Zhou et al\textsuperscript{20} who reported histological renal tubular damage.

CONCLUSIONS

A study involving 75 β thalassemia major patients receiving more than 6 units of blood transfusion within the last 6 months revealed, 94.7% had increased transferrin saturation and 40.0% had hemochromatosis. Seventy-three point four percent had microalbuminuria, one (1.3%) had albuminuria, 21.3% had increased urinary β2-m excretion. A total of 78.6% of all patients showed renal dysfunction.

No correlation was found between transferrin saturation and microalbuminuria, while significant but very weak positive correlation was found between hemochromatosis and increased urinary β2-m and β2-m/creatinine ratio. Although there was no correlation between hemochromatosis and microalbuminuria, (73.4%) of patients with microalbuminuria was quite high. This suggested that glomerular dysfunction happens (earlier in the course of disease) in an earlier stage of the disease process. Probably the high incidence of microalbuminuria is also attributed to defective ability of the proximal tubular cells to reabsorb protein besides dysfunction of the glomeruli.
Microalbumin could be suggested as a relatively sensitive parameter to detect renal dysfunction. This study verifies that hemochromatosis can cause renal dysfunction.

We suggest testing for microalbumin to determine any renal damage by iron deposit in the kidneys, or if possible urinary β2-m estimation as a routine test for β thalassemia major patients to determine therapeutic desferrioxamine (DFO) dosage, because DFO can cause renal toxicity.

REFERENCES

18. Suryaningsih V. Albumin/creatinine ratio in the morning urine sample as an alternative method for 24-hours urinary albumin excretion in NIDDM patients. Thesis. Department of Clinical Pathology, Medical School, University of Indonesia, Jakarta. 2000 (In Indonesian)